Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, effective February 1, 2025, Nova Scotia is publicly funding Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan injection), ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

Or it could be the last of the lanthanides - lutetium. After completing my PhD, I carried out postdoctoral research trying to make new organometallic compounds of the metallic elements with electrons ...

Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase I for Neuroendocrine Cancer. According to GlobalData, Phase I drugs for ...

By breaking apart the nuclei of platinum, physicists led by Oleg Tarasov of Michigan State University have discovered new isotopes of rare-Earth elements thulium, ytterbium, and lutetium.

Lutetium-177 PSMA Radioligand Therapy for Advanced Prostate Cancer: Reviewing the Pivotal VISION and TheraP Trials - Michael Morris PSMA and RLT: The VISION and TheraP Trials "Presentation" - Michael ...

This was further bolstered by Novartis's acquisition of Advanced Accelerator Applications, the developer of Pluvicto (lutetium [177Lu] vipivotide tetraxetan), which targets prostate-specific ...

We had faced challenges with making enough PLUVICTO. Until recently, Novartis manufactured this treatment commercially only at its facility in Ivrea, Italy. Interruptions in the process—from ...

In recent years there has been an ongoing debate concerning the placement of lawrencium, and also element 71 or lutetium. Some periodic tables place lutetium and lawrencium one above the other, as the ...